PE20080192A1 - PIRIDIN[3,4-b]PIRAZINONAS - Google Patents

PIRIDIN[3,4-b]PIRAZINONAS

Info

Publication number
PE20080192A1
PE20080192A1 PE2007000483A PE2007000483A PE20080192A1 PE 20080192 A1 PE20080192 A1 PE 20080192A1 PE 2007000483 A PE2007000483 A PE 2007000483A PE 2007000483 A PE2007000483 A PE 2007000483A PE 20080192 A1 PE20080192 A1 PE 20080192A1
Authority
PE
Peru
Prior art keywords
dysfunction
metoxypyridin
pirazin
propoxyethyl
pyrid
Prior art date
Application number
PE2007000483A
Other languages
English (en)
Inventor
Robert O Huges
Andrew Simon Bell
David Graham Brown
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Nischke
John Major Molyneaux
Joseph Blair Moon
Rogier
Michael Brent Tollefson
John Keith Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20080192A1 publication Critical patent/PE20080192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R2 ES ARILO, ANILLO HETEROCICLILO DE 3-10 MIEMBROS; R6A y R6B JUNTO CON AL NITROGENO AL QUE ESTAN UNIDOS FORMAN UN ANILLO HETEROCICLILO PARCIAL O TOTALMENTE SATURADO DE 3 -14 MIEMBROS; R8 ES ALQUILO SUSTITUIDO O NO POR HALOGENO, CIANO, HIDROXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 7-(6-METOXIPIRIDIN-3-IL)-3-(PIPERAZIN-1-IL)-1-(2-PROPOXIETIL)PIRIDO[3,4-b]PIRAZIN-2(1H)-ONA; 3-[(1R,4R)-2,5-DIAZABICICLO[2.2.1]HEPT-2-IL]-7-(6-METOXIPIRIDIN-3-IL)-1-(2-PROPOXIETIL)PIRIDO[3,4-b]PIRAZIN-2(1H)-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON INHIBIDORES DE FOSFODIESTERASA DE TIPO 5 ESPECIFICA DE MONOFOSFATO DE GUANILATO CICLICO (PDE-5), UTILES EN EL TRATAMIENTO DE AFECCIONES CARDIOVASCULARES, AFECCIONES PULMONARES, DISFUNCION RENAL, AFECCIONES METABOLICAS, DISFUNCION SEXUAL Y AFECCIONES DEL SISTEMA NERVIOSO CENTRAL
PE2007000483A 2006-04-21 2007-04-19 PIRIDIN[3,4-b]PIRAZINONAS PE20080192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
PE20080192A1 true PE20080192A1 (es) 2008-03-01

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000483A PE20080192A1 (es) 2006-04-21 2007-04-19 PIRIDIN[3,4-b]PIRAZINONAS

Country Status (42)

Country Link
US (1) US7902195B2 (es)
EP (1) EP2013208B1 (es)
JP (1) JP4436892B2 (es)
KR (1) KR101061328B1 (es)
CN (1) CN101454320B (es)
AP (1) AP2408A (es)
AR (1) AR060525A1 (es)
AT (1) ATE513831T1 (es)
AU (1) AU2007242555B2 (es)
BR (1) BRPI0710658A2 (es)
CA (1) CA2649775C (es)
CR (1) CR10327A (es)
CU (1) CU23777B7 (es)
CY (1) CY1111739T1 (es)
DK (1) DK2013208T3 (es)
DO (1) DOP2007000080A (es)
EA (1) EA014919B1 (es)
EC (1) ECSP088803A (es)
ES (1) ES2366239T3 (es)
GT (1) GT200700035A (es)
HK (1) HK1133875A1 (es)
HR (1) HRP20110539T1 (es)
IL (1) IL194591A (es)
MA (1) MA30352B1 (es)
ME (1) MEP23808A (es)
MX (1) MX2008012456A (es)
MY (1) MY148583A (es)
NL (1) NL2000583C2 (es)
NO (1) NO20084129L (es)
NZ (1) NZ571540A (es)
PA (1) PA8724201A1 (es)
PE (1) PE20080192A1 (es)
PL (1) PL2013208T3 (es)
RS (2) RS51885B (es)
SI (1) SI2013208T1 (es)
SV (1) SV2008003074A (es)
TN (1) TNSN08408A1 (es)
TW (1) TWI337609B (es)
UA (1) UA92637C2 (es)
UY (1) UY30291A1 (es)
WO (1) WO2007122466A1 (es)
ZA (1) ZA200808283B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2408A (en) 2006-04-21 2012-05-30 Pfizer Prod Inc Pyridine[3,4-B]pyrazinones.
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
AU2009221213B2 (en) * 2008-03-05 2014-02-27 Merck Patent Gmbh Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
TW201020233A (en) * 2008-10-09 2010-06-01 Kyorin Seiyaku Kk Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
BR112012009751A2 (pt) * 2009-10-26 2020-09-24 Signal Pharmaceuticals, Llc métodos de síntese e purificação de heteroarila
BR112013008983A2 (pt) 2010-10-15 2016-07-05 Gilead Sciences Inc composições e métodos de tratamento da hipertensão pulmonar
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014128585A1 (en) 2013-02-19 2014-08-28 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
AU2015242330B2 (en) 2014-04-01 2017-08-17 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
MD20160105A2 (ro) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EP3177624B1 (en) 2014-08-06 2019-05-01 Pfizer Inc Imidazopyridazine compounds
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
JP7046018B2 (ja) 2016-07-01 2022-04-01 ファイザー・インク 神経性疾患および神経変性疾患を処置するための５，７－ジヒドロピロロピリジン誘導体
US11198692B2 (en) 2017-06-22 2021-12-14 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
FI3768669T3 (fi) 2018-03-23 2023-04-26 Pfizer Piperatsiiniatsaspirojohdannaisia
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
TW274550B (es) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
CN1503797A (zh) * 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005040337A2 (en) * 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
CN1842526A (zh) * 2003-06-26 2006-10-04 麦克公司 苯并二氮杂䓬cgrp受体拮抗剂
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
CA2608672A1 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
KR20080052611A (ko) * 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AP2408A (en) 2006-04-21 2012-05-30 Pfizer Prod Inc Pyridine[3,4-B]pyrazinones.

Also Published As

Publication number Publication date
IL194591A (en) 2012-07-31
CR10327A (es) 2008-10-21
NO20084129L (no) 2008-10-29
CU20080194A7 (es) 2011-03-21
SI2013208T1 (sl) 2011-09-30
CA2649775A1 (en) 2007-11-01
MA30352B1 (fr) 2009-04-01
ZA200808283B (en) 2009-11-25
TWI337609B (en) 2011-02-21
JP2009534368A (ja) 2009-09-24
NZ571540A (en) 2010-10-29
AP2008004640A0 (en) 2008-10-31
JP4436892B2 (ja) 2010-03-24
DOP2007000080A (es) 2007-11-15
AR060525A1 (es) 2008-06-25
WO2007122466A1 (en) 2007-11-01
BRPI0710658A2 (pt) 2011-08-16
DK2013208T3 (da) 2011-08-15
SV2008003074A (es) 2010-01-12
RS20080484A (en) 2009-07-15
AU2007242555A1 (en) 2007-11-01
GT200700035A (es) 2008-02-05
CU23777B7 (es) 2012-02-15
EP2013208A1 (en) 2009-01-14
PA8724201A1 (es) 2009-08-26
EA014919B1 (ru) 2011-04-29
CN101454320A (zh) 2009-06-10
NL2000583A1 (nl) 2007-10-23
CA2649775C (en) 2011-05-31
AU2007242555B2 (en) 2010-12-16
US20070249615A1 (en) 2007-10-25
PL2013208T3 (pl) 2011-10-31
ATE513831T1 (de) 2011-07-15
KR101061328B1 (ko) 2011-08-31
HRP20110539T1 (hr) 2011-08-31
HK1133875A1 (en) 2010-04-09
EA200801998A1 (ru) 2009-04-28
US7902195B2 (en) 2011-03-08
MEP23808A (en) 2010-06-10
MY148583A (en) 2013-04-30
ECSP088803A (es) 2008-11-27
RS51885B (en) 2012-02-29
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
KR20080110930A (ko) 2008-12-19
UY30291A1 (es) 2007-11-30
MX2008012456A (es) 2008-10-10
TW200808794A (en) 2008-02-16
CY1111739T1 (el) 2015-10-07
EP2013208B1 (en) 2011-06-22
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
TNSN08408A1 (fr) 2010-04-14
ES2366239T3 (es) 2011-10-18

Similar Documents

Publication Publication Date Title
PE20080192A1 (es) PIRIDIN[3,4-b]PIRAZINONAS
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
TWI598351B (zh) Ｒｓｖ抗病毒化合物
US9765074B2 (en) Inhibitors of the renal outer medullary potassium channel
PE20142293A1 (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
RU2410387C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИН-4-ОН 2-ИНДОЛИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ
CO6251264A2 (es) Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k
US10000484B2 (en) Inhibitors of the renal outer medullary potassim channel
PE20030415A1 (es) Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v
JP2016505020A5 (es)
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
AR056888A1 (es) Derivados de heterociclil imidazol
JP2009520804A5 (es)
BR112021005896A2 (pt) moduladores da monoacilglicerol lipase
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
EA200801000A1 (ru) Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)
KR20150036142A (ko) 신장 외수질 칼륨 채널의 억제제로서 사용하기 위한 스피로 - 융합된 피페리딘 유도체
TW200848420A (en) Compounds
GB0507601D0 (en) Compounds
ES2586527T9 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
AR053548A1 (es) Derivados de oxiindol
PE20191236A1 (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos
JP2016505010A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed